Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> PDGFR

PDGFR

PDGFR (platelet-derived growth factor receptor) is a group of cell surface tyrosine kinase receptors for members of the PDGF (platelet-derived growth factor) family.

Products for  PDGFR

  1. Cat.No. Product Name Information
  2. GC62291 (Z)-Orantinib

    (Z)-SU6668; (Z)-TSU-68

     (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (Z)-Orantinib Chemical Structure
  3. GC18167 AC710

    A potent and selective PDGFR family inhibitor

     AC710 Chemical Structure
  4. GC35225 AC710 Mesylate AC710 Mesylate is a potent PDGFR inhibitor with Kds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively. AC710 Mesylate Chemical Structure
  5. GC38645 AG 1295 AG 1295 Chemical Structure
  6. GC16235 AG-1295

    NSC 380341,Tyrphostin AG-1295

     potent and selective inhibitor of PDGF receptor kinase AG-1295 Chemical Structure
  7. GC11712 AG-370

    NSC 651712

     PDGFR inhibitor AG-370 Chemical Structure
  8. GC16391 Amuvatinib (MP-470, HPK 56)

    HPK56, MP470

     A multi-targeted RTK inhibitor Amuvatinib (MP-470, HPK 56) Chemical Structure
  9. GC33362 Amuvatinib hydrochloride (MP470 hydrochloride)

    MP470 hydrochloride; HPK 56 hydrochloride

     Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant c-Kit, PDGFRα, Flt3, c-Met and c-Ret. Amuvatinib hydrochloride (MP470 hydrochloride) (MP470 hydrochloride) is also a DNA repair suppressor through suppression of DNA repair protein RAD51, thereby disrupting DNA damage repair. Antineoplastic activity. Amuvatinib hydrochloride (MP470 hydrochloride) Chemical Structure
  10. GC45677 Anlotinib (hydrochloride) A neuropeptide with diverse biological activities Anlotinib (hydrochloride) Chemical Structure
  11. GC70992 Ansornitinib Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib Chemical Structure
  12. GC60601 ARRY-382 ARRY-382 Chemical Structure
  13. GC19074 Avapritinib

    Avapritinib

     Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. Avapritinib Chemical Structure
  14. GC12216 Axitinib (AG 013736)

    AG 013736

     Axitinib (AG 013736) is an orally active specific vascular endothelial growth factor receptor (VEGFR) inhibitor that targets VEGFR-1, VEGFR-2, and VEGFR-3 with IC50 values of 0.1nM, 0.2nM, and 0.1-0.3nM, respectively. Axitinib (AG 013736) Chemical Structure
  15. GC73370 AXL-IN-13 AXL-IN-13 is a potent and orally active AXL inhibitor (IC50: 1.6 nM, Kd: 0.26 nM). AXL-IN-13 Chemical Structure
  16. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932 Chemical Structure
  17. GC46924 BIBF 1120-13C-d3

    Nintedanib-13C-d3

     A neuropeptide with diverse biological activities BIBF 1120-13C-d3 Chemical Structure
  18. GC16421 Cediranib (AZD217)

    AZD 2171, ZD 2171

     Cediranib (AZD217) (AZD2171) is a highly potent, orally available VEGFR tyrosine kinase inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib (AZD217) Chemical Structure
  19. GC33004 Cediranib maleate (AZD-2171 maleate) Cediranib maleate (AZD-2171 maleate) (AZD-2171 maleate) is a highly potent, orally available VEGFR inhibitor with IC50s of <1, <3, 5, 5, 36, 2 nM for Flt1, KDR, Flt4, PDGFRα, PDGFRβ, c-Kit, respectively. Cediranib maleate (AZD-2171 maleate) Chemical Structure
  20. GC62145 Chiauranib

    CS2164

     Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects. Chiauranib Chemical Structure
  21. GC15739 CHIR-124 Chk1 inhibitor,novel and potent CHIR-124 Chemical Structure
  22. GC12980 CP-673451 PDGFRα/β inhibitor,potent and selective CP-673451 Chemical Structure
  23. GC14906 Crenolanib (CP-868596)

    CP-868596;CP 868596;CP868596

     Crenolanib (CP-868596) is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with Kds of 0.74 nM and 2.1 nM/3.2 nM, respectively. Crenolanib (CP-868596) Chemical Structure
  24. GC67774 CT52923 CT52923 Chemical Structure
  25. GC91419 CYY292 CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively). CYY292 Chemical Structure
  26. GC11171 DCC-2618

    DCC2618;DCC 2618

     A dual inhibitor of c-Kit and c-MET DCC-2618 Chemical Structure
  27. GC39623 DCC-3014

    DCC-3014

     DCC-3014 (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of <0.01 μM and 0.1-1 μM, respectively. DCC-3014 Chemical Structure
  28. GC17024 DMPQ dihydrochloride PDGFRβ inhibitor DMPQ dihydrochloride Chemical Structure
  29. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  30. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  31. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  32. GC32867 Flumatinib (HHGV678)

    HH-GV-678

     Flumatinib (HHGV678) (HHGV678) is an orally available, selective inhibitor of Bcr-Abl. Flumatinib (HHGV678) inhibits c-Abl, PDGFRβ and c-Kit with IC50s of 1.2 nM, 307.6 nM and 665.5 nM, respectively. Flumatinib (HHGV678) Chemical Structure
  33. GC13914 Flumatinib mesylate PDGRFβ inhibitor Flumatinib mesylate Chemical Structure
  34. GC33201 GZD856 GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 Chemical Structure
  35. GC62453 GZD856 formic GZD856 formic is a potent and orally active PDGFRα/β inhibitor, with IC50s of 68.6 and 136.6 nM, respectively. GZD856 formic is also a Bcr-AblT315I inhibitor, with IC50s of 19.9 and 15.4?nM for native Bcr-Abl and the T315I mutant. GZD856 formic has antitumor activity. GZD856 formic Chemical Structure
  36. GC43885 Hypothemycin

    NSC 354462

     A resorcylic acid lactone polyketide Hypothemycin Chemical Structure
  37. GC34159 Ilorasertib (ABT-348)

    ABT-348

     Ilorasertib (ABT-348) (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib (ABT-348) also is a potent VEGF, PDGF inhibitor. Ilorasertib (ABT-348) has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib (ABT-348) Chemical Structure
  38. GC38519 Ilorasertib hydrochloride

    ABT-348 hydrochloride

     Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC50s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Ilorasertib hydrochloride Chemical Structure
  39. GC10314 Imatinib (STI571) Imatinib (STI571) (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib (STI571) (STI571) works by binding close to the ATP binding site, locking it in a closed or self-inhibited conformation, therefore inhibiting the enzyme activity of the protein semicompetitively. Imatinib (STI571) also is an inhibitor of SARS-CoV and MERS-CoV. Imatinib (STI571) Chemical Structure
  40. GC60930 Imatinib D4 Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D4 Chemical Structure
  41. GC39612 Imatinib D8 Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity. Imatinib D8 Chemical Structure
  42. GC15263 Imatinib hydrochloride V-Abl/c-Kit/PDGFR inhibitor Imatinib hydrochloride Chemical Structure
  43. GC11759 Imatinib Mesylate (STI571)

    CGP57148B, STI571

     Imatinib Mesylate (STI571) (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits c-Kit, Bcr-Abl, and PDGFR (IC50=100 nM) tyrosine kinases. Imatinib Mesylate (STI571) Chemical Structure
  44. GC18168 JI-101

    CGI1842

    An orally active inhibitor

     JI-101 Chemical Structure
  45. GC38502 JNJ-10198409 A potent PDGF tyrosine kinase inhibitor JNJ-10198409 Chemical Structure
  46. GC14544 JNJ-10198409 inhibitor of platelet-derived growth factor (PDGF-BB) tyrosine kinase JNJ-10198409 Chemical Structure
  47. GC13264 Ki20227

    Ki 20227;Ki-20227

     A c-Fms kinase inhibitor Ki20227 Chemical Structure
  48. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

     E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.  Lenvatinib (E7080) Chemical Structure
  49. GC36438 Lenvatinib mesylate

    E-7080

     An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  50. GC45754 Lenvatinib-d4

    E7080-d4

     A neuropeptide with diverse biological activities Lenvatinib-d4 Chemical Structure
  51. GC17958 Linifanib (ABT-869)

    Linifanib

     Linifanib (ABT-869) (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC50s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (ABT-869) shows prominent antitumor activity. Linifanib (ABT-869) has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib (ABT-869) is a specific miR-10b inhibitor that blocks miR-10b biogenesis. Linifanib (ABT-869) Chemical Structure
  52. GC13410 Masitinib (AB1010)

    AB-1010, Masican, Masiviera

     Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib (AB1010) Chemical Structure
  53. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  54. GC36596 Methylnissolin

    (-)-Methylnissolin

     Methylnissolin (Astrapterocarpan), isolated from Astragalus membranaceus, inhibits platelet-derived growth factor (PDGF)-BB-induced cell proliferation with an IC50 of 10 μM. Methylnissolin Chemical Structure
  55. GC16337 MK-2461 C-Met (WT/mutants) inhibitor MK-2461 Chemical Structure
  56. GC40567 N-(p-Coumaroyl) Serotonin

    NSC 369503

     N-(p-Coumaroyl) serotonin is an antioxidative phenolic naturally found in plants, including safflower seed and millet grain. N-(p-Coumaroyl) Serotonin Chemical Structure
  57. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  58. GC36745 Nintedanib esylate

    Nintedanib

     Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). Nintedanib esylate Chemical Structure
  59. GC34126 NVP-ACC789 (ACC-789) NVP-ACC789 (ACC-789) is an inhibitor of human VEGFR-1, VEGFR-2 (mouse VEGFR-2), VEGFR-3 and PDGFR-β with IC50s of 0.38, 0.02 (0.23), 0.18, 1.4 μM, respectively. NVP-ACC789 (ACC-789) Chemical Structure
  60. GC44474 NVP-AEW541 (hydrochloride) Insulin-like growth factor 1 receptor (IGF-1R) is a receptor tyrosine kinase whose activation leads to angiogenesis as well as cell proliferation, survival, transformation, and metastasis. NVP-AEW541 (hydrochloride) Chemical Structure
  61. GC69619 Olaratumab

    IMC-3G3; LY3012207

    Olaratumab (IMC-3G3; LY3012207) is a human monoclonal IgG1 antibody that targets platelet-derived growth factor receptor alpha (PDGFRα) and has anti-tumor activity.

     Olaratumab Chemical Structure
  62. GC14676 Pacritinib (SB1518)

    SB1518

     Pacritinib (SB1518) (SB1518) is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib (SB1518) also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib (SB1518) Chemical Structure
  63. GC16327 Pazopanib (GW-786034)

    GSK-VEG10003, GW786034B

     A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  64. GC12730 Pazopanib Hydrochloride

    GW786034;Votrient;Armala;GW 786034;GW-786034

     VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  65. GC72911 Pazopanib-13C,d3 hydrochloride

    GW786034-13C,d3 hydrochloride

     Pazopanib-13C,d3 (drochloride) is the deuterium and 13C labeled Pazopanib drochloride. Pazopanib-13C,d3 hydrochloride Chemical Structure
  66. GC44583 PD 089828

    EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor

     PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM). PD 089828 Chemical Structure
  67. GC65366 PDGFRα kinase inhibitor 1 PDGFRα kinase inhibitor 1 is a highly selective type II PDGFRα kinase inhibitor with IC50s of 132 nM and 6115 nM for PDGFRα and PDGFRβ, respectively. PDGFRα kinase inhibitor 1 Chemical Structure
  68. GC14396 Ponatinib (AP24534)

    AP 24534

     Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  69. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  70. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121 Chemical Structure
  71. GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values. PP58 Chemical Structure
  72. GC48022 Radotinib-d6

    IY-5511

     A neuropeptide with diverse biological activities Radotinib-d6 Chemical Structure
  73. GC14606 Regorafenib hydrochloride A multi-kinase inhibitor Regorafenib hydrochloride Chemical Structure
  74. GC14534 Regorafenib monohydrate A multi-kinase inhibitor Regorafenib monohydrate Chemical Structure
  75. GC37538 Ripretinib

    DCC-2618

     Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2). DCC-2618 exerts antineoplastic effect and induces apoptosis. Ripretinib Chemical Structure
  76. GN10603 Sennoside B Sennoside B Chemical Structure
  77. GC62114 Seralutinib

    GB002; PK10571

     Seralutinib (GB002) is an inhaled PDGFRα and PDGFRβ inhibitor. Seralutinib Chemical Structure
  78. GC17369 Sorafenib

    BAY 43-9006

    Sorafenib acts as a multi-kinase inhibitor, targeting Raf-1 and B-Raf with IC50 values of 6 nM and 22 nM, respectively.

     Sorafenib Chemical Structure
  79. GC12686 SU 16f

    SU16F

     PDGFRβ inhibitor SU 16f Chemical Structure
  80. GC14660 SU 5402 An inhibitor of VEGFR2, FGFR1, and PDGFRβ SU 5402 Chemical Structure
  81. GC14733 SU14813

    SU-14813;SU 14813

     A dual VEGFR and PDGFR family kinase inhibitor SU14813 Chemical Structure
  82. GC14315 SU14813 maleate A dual VEGFR and PDGFR family kinase inhibitor SU14813 maleate Chemical Structure
  83. GC38034 SU16f A potent inhibitor of PDGFRβ SU16f Chemical Structure
  84. GC61957 SU4984 SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer. SU4984 Chemical Structure
  85. GC17651 Sunitinib Sunitinib (SU 11248) is an orally active multi-target receptor tyrosine kinase inhibitor with IC50 values of 80 nM and 2 nM for vascular endothelial growth factor receptor (VEGFR2) and platelet-derived growth factor receptor (PDGFRβ), respectively. Sunitinib Chemical Structure
  86. GC48118 Sunitinib-d10 An internal standard for the quantification of sunitinib Sunitinib-d10 Chemical Structure
  87. GC10220 TAK-593 dual VEGFR/PDGFR inhibitor TAK-593 Chemical Structure
  88. GC49700 Takeda-6d Takeda-6d Chemical Structure
  89. GC15254 Tandutinib (MLN518)

    CT 53518, MLN518

     Tandutinib (MLN518) (MLN518) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib (MLN518) can be used for acute myelogenous leukemia (AML). Tandutinib (MLN518) has the ability to cross the blood-brain barrier. Tandutinib (MLN518) Chemical Structure
  90. GC38853 Tandutinib hydrochloride

    MLN518 hydrochloride; CT53518 hydrochloride

     Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier. Tandutinib hydrochloride Chemical Structure
  91. GC11763 Telatinib (BAY 57-9352)

    BAY 579352;BAY 57 9352

     Telatinib (BAY 57-9352) (Bay 57-9352) is an orally active, small molecule inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit with IC50s of 6, 4, 15 and 1 nM, respectively. Telatinib (BAY 57-9352) Chemical Structure
  92. GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Chemical Structure
  93. GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Hydrochloride Chemical Structure
  94. GC11622 TG 100801 TG 100801 Chemical Structure
  95. GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100801 Hydrochloride Chemical Structure
  96. GC10719 Toceranib

    PHA 291639, SU11654

     A multi-targeted receptor tyrosine kinase inhibitor Toceranib Chemical Structure
  97. GC37808 Toceranib phosphate Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors . Toceranib phosphate Chemical Structure
  98. GC66385 Tovetumab

    MEDI-575

     Tovetumab (MEDI-575) is an anti-PDGFRα monoclonal antibody that selectively blocks the PDGFRα signal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lung cancer (NSCLC). Tovetumab Chemical Structure
  99. GC32458 Trapidil (AR-12008)

    Triazolopyrimidine

     Trapidil (AR-12008) is a vasodilator, is an antiplatelet drug with specific platelet-derived growth factor. Trapidil (AR-12008) Chemical Structure
  100. GC16732 TSU-68 (SU6668,Orantinib)

    NSC 702827, Orantinib, TSU68

     TSU-68 (SU6668,Orantinib) (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively. TSU-68 (SU6668,Orantinib) Chemical Structure
  101. GC34026 Tyrosine kinase-IN-1 Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. Tyrosine kinase-IN-1 Chemical Structure

Items 1 to 100 of 105 total

per page
  1. 1
  2. 2

Set Descending Direction